Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas.
26. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G.
Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of
drug-induced pregnancy. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during
long-term treatment are required. 34. Jones J, Bashir T, Olney J,
Wheatley T. Cabergoline treatment for a large macroprolactinoma throughout pregnancy.
Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
40. Laloi-Michelin M, Ciraru-Vigneron N, Meas T.
Cabergoline treatment of pregnant women with macroprolactinomas.
31. Konopka P, Raymond JP, Merceron RE, Seneze J.
Continuous administration of bromocriptine in the prevention of neurological complications
in pregnant women with prolactinomas. 19. Colao A, Di Sarno A, Guerra E, De Leo M, Mentone A,
Lombardi G. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
|
